中华流行病学杂志
中華流行病學雜誌
중화류행병학잡지
CHINESE JOURNAL OF EPIDEMIOLOGY
2013年
2期
187-190
,共4页
乳腺肿瘤,男性%激素受体%人类表皮生长因子受体-2
乳腺腫瘤,男性%激素受體%人類錶皮生長因子受體-2
유선종류,남성%격소수체%인류표피생장인자수체-2
Male breast neoplasia%Hormone receptor%Human epidermal growth factor receptor-2
目的 探讨男性乳腺癌(MBC)患者临床病理特征及其预后.方法 回顾性分析天津医科大学附属肿瘤医院2002年3月至2012年3月71例MBC患者的临床病理及生存资料.结果 MBC患者年龄43～84(M=62)岁,中位年龄大于同期女性乳腺癌(FBC)患者(t=6.355,P=0.000),与同期FBC例数之比为0.42％(71:16 796)；MBC病理类型以浸润性导管癌(x2=29.875,P=0.000)、临床分期以＞ⅢA(x2=13.377,P=0.037)多见.MBC患者雌激素受体阳性率明显高于FBC患者,而人类表皮生长因子受体-2(HER-2)阳性率明显低于FBC患者(x2=3.741,P=0.048；x2=12.845,P=0.002).单因素和多因素分析发现MBC患者预后比FBC患者差(P=0.004,P=0.046).MBC患者的HER-2表达水平是影响其预后的重要因素(x2=4.219,P=0.040).结论 MBC与FBC的临床特征及预后均存在显著差异.HER-2阳性可能对MBC的预后及治疗有重要意义.
目的 探討男性乳腺癌(MBC)患者臨床病理特徵及其預後.方法 迴顧性分析天津醫科大學附屬腫瘤醫院2002年3月至2012年3月71例MBC患者的臨床病理及生存資料.結果 MBC患者年齡43～84(M=62)歲,中位年齡大于同期女性乳腺癌(FBC)患者(t=6.355,P=0.000),與同期FBC例數之比為0.42％(71:16 796)；MBC病理類型以浸潤性導管癌(x2=29.875,P=0.000)、臨床分期以＞ⅢA(x2=13.377,P=0.037)多見.MBC患者雌激素受體暘性率明顯高于FBC患者,而人類錶皮生長因子受體-2(HER-2)暘性率明顯低于FBC患者(x2=3.741,P=0.048；x2=12.845,P=0.002).單因素和多因素分析髮現MBC患者預後比FBC患者差(P=0.004,P=0.046).MBC患者的HER-2錶達水平是影響其預後的重要因素(x2=4.219,P=0.040).結論 MBC與FBC的臨床特徵及預後均存在顯著差異.HER-2暘性可能對MBC的預後及治療有重要意義.
목적 탐토남성유선암(MBC)환자림상병리특정급기예후.방법 회고성분석천진의과대학부속종류의원2002년3월지2012년3월71례MBC환자적림상병리급생존자료.결과 MBC환자년령43～84(M=62)세,중위년령대우동기녀성유선암(FBC)환자(t=6.355,P=0.000),여동기FBC례수지비위0.42％(71:16 796)；MBC병리류형이침윤성도관암(x2=29.875,P=0.000)、림상분기이＞ⅢA(x2=13.377,P=0.037)다견.MBC환자자격소수체양성솔명현고우FBC환자,이인류표피생장인자수체-2(HER-2)양성솔명현저우FBC환자(x2=3.741,P=0.048；x2=12.845,P=0.002).단인소화다인소분석발현MBC환자예후비FBC환자차(P=0.004,P=0.046).MBC환자적HER-2표체수평시영향기예후적중요인소(x2=4.219,P=0.040).결론 MBC여FBC적림상특정급예후균존재현저차이.HER-2양성가능대MBC적예후급치료유중요의의.
Objective Male breast cancer (MBC) is a rare disease,with clinical and prognostic features still controversial.The aim of this study was to discuss the clinical characteristics and prognosis of MBC.Methods Clinical data related to 71 MBC patients was reviewed.Results The radio of MBC to female breast cancer (FBC) was 42:10 000.Age related to the diagnosis of MBC ranged from 43 to 84 years with the median age as 62 years old,older than the FBC patients (t=6.355,P=0.000).The percentage of invasive ducal carcinoma in MBC patients was much higher than in FBC patients (x2=29.875,P=0.000).The positive rate of estrogen receptor (ER) was significantly higher than those in FBC patients and the positive rates of human epidermal growth factor receptor-2 (HER-2) were less frequently (x2=3.741,P=0.048 and x2=12.845,P=0.002)seen.Data from the univariate and multivariate analysis showed that the 3-,5-and 10-year survivalrates of MBC were 82.6％,74.0％ and 47.4％ respectively,significantly higher than those in FBCpatients (P=0.004,P=0.046).Patients with positive HER-2 showed worse prognosis than HER-2 negative patients in MBC patients (x2=4.219,P=0.040).Conclusion There were significant clinic-pathologic and prognostic differences between FBC and MBC patients.The HER-2 positivity seemed to be an important factor for the prognosis and treatment of patients with MBC.
